We demonstrate that the mechanism underlying the oncogenic effect of FTO is based on its capability of MALAT1 demethylation and the regulatory functions on the MALAT/miR‐384/MAL2 axis, which are three of the crucial molecular biomarkers clinically relevant to bladder cancer. This evidence concerns the gene FTO and urinary bladder carcinoma.